Literature DB >> 29617742

A Statewide Antibiotic Stewardship Collaborative to Improve the Diagnosis and Treatment of Urinary Tract and Skin and Soft Tissue Infections.

Timothy C Jenkins1,2,3,4,5, Teresa Hulett6, Bryan C Knepper3, Katherine C Shihadeh7, Marc J Meyer8, Gerard R Barber9, John H Hammer10, Heidi L Wald4,6.   

Abstract

Background: Colorado hospitals participated in a statewide collaborative to improve the management of inpatient urinary tract infections (UTIs) and skin and soft tissue infections (SSTIs). We evaluated the effects of the intervention on diagnostic accuracy and antibiotic use.
Methods: The main collaborative outcomes were proportion of UTI diagnoses that met criteria for symptomatic UTI; exposure to fluoroquinolones (UTI only); duration of therapy (UTIs and SSTIs); and exposure to antibiotics with broad gram-negative activity (SSTIs only). Outcomes were compared between pre-intervention and intervention periods overall and by hospital. Secondary analyses were changes in outcome trends by time series analysis.
Results: Twenty-six hospitals, including 9 critical access hospitals, participated in the collaborative. Data were reported for 4060 UTIs and 1759 SSTIs. Between the pre-intervention and intervention periods, the proportion of diagnosed UTIs that met criteria for symptomatic UTI was similar (51% vs 54%, respectively; P = .10), exposure to fluoroquinolones declined (49% vs 41%; P < .001), and the median duration of therapy was unchanged (7 vs 7 days; P = .99). Among SSTIs, exposure to antibiotics with broad gram-negative activity declined (61% vs 53%; P = .001) and the median duration of therapy declined (11 vs 10 days; P = .03). There was substantial variation in performance among hospitals. By time series analysis, only the declining trend of fluoroquinolone use was significant (P = .03). Conclusions: The collaborative model is a feasible approach to engage hospitals in a common antibiotic stewardship intervention. Performance improvement was observed for several outcomes but varied substantially by hospital.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29617742     DOI: 10.1093/cid/ciy268

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  5 in total

Review 1.  Antibiotic Overuse and Stewardship at Hospital Discharge: The Reducing Overuse of Antibiotics at Discharge Home Framework.

Authors:  Valerie M Vaughn; Adam L Hersh; Emily S Spivak
Journal:  Clin Infect Dis       Date:  2022-05-03       Impact factor: 20.999

2.  Inpatient Management of Uncomplicated Skin and Soft Tissue Infections in 34 Veterans Affairs Medical Centers: A Medication Use Evaluation.

Authors:  Jesse D Sutton; Ronald Carico; Muriel Burk; Makoto M Jones; XiangMing Wei; Melinda M Neuhauser; Matthew Bidwell Goetz; Kelly L Echevarria; Emily S Spivak; Francesca E Cunningham
Journal:  Open Forum Infect Dis       Date:  2020-01-27       Impact factor: 3.835

3.  A Deeper Dive Into Antibiotic Stewardship Needs: A Multihospital Survey.

Authors:  Valerie M Vaughn; Lindsay A Petty; Scott A Flanders; Anurag N Malani; Twisha Patel; Steven J Bernstein; Lama M Hsaiky; Rama Thyagarajan; Danielle Osterholzer; Elizabeth McLaughlin; Jennifer K Horowitz; Tejal N Gandhi
Journal:  Open Forum Infect Dis       Date:  2020-01-11       Impact factor: 3.835

4.  A Statewide Collaborative Quality Initiative to Improve Antibiotic Duration and Outcomes in Patients Hospitalized With Uncomplicated Community-Acquired Pneumonia.

Authors:  Valerie M Vaughn; Tejal N Gandhi; Timothy P Hofer; Lindsay A Petty; Anurag N Malani; Danielle Osterholzer; Lisa E Dumkow; David Ratz; Jennifer K Horowitz; Elizabeth S McLaughlin; Tawny Czilok; Scott A Flanders
Journal:  Clin Infect Dis       Date:  2022-08-31       Impact factor: 20.999

5.  Increasing Guideline-Concordant Durations of Antibiotic Therapy for Acute Otitis Media.

Authors:  Holly M Frost; Yingbo Lou; Amy Keith; Andrew Byars; Timothy C Jenkins
Journal:  J Pediatr       Date:  2021-07-15       Impact factor: 4.406

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.